Contribution of the atherogenic lipoprotein profile to the development of arterial hypertension

Bratislava Medical Journal

Volumn 112, Issue 1, 2011, Pages 4-7

  Oravec, S ^a   Dukat, A ^a   Gavornik, P ^a   Caprnda, M ^a   Kucera, M ^a   Ocadlik, I ^a  

^a Bratislava   (Slovakia)

Author keywords

Atherogenic normolipemia; Atherogenic vs. non atherogenic lipoprotein profile

Indexed keywords

LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PROSTAGLANDIN;

ARTICLE; ATHEROSCLEROSIS; BLOOD; BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY;

ATHEROSCLEROSIS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROSTAGLANDINS;

EID: 78751622167     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Felmeden DC, Spencer CGC, Blann AD, Beewers DG, Lip GY. Low-Density Lipoprotein subfractions and cardiovascular risk in hypertension. Relationship to endothelial dysfunction and effects of treatment. Hypertension 2003; 41 (3): 528-533.
2. Whitworth JA. World Health Organisation (WHO), International Society of Hypertension (ISH) statement on management of hypertension. J. Hypertension 2003; 21 (11): 1983-1992.
3. Horký K. Systémová arteriálni hypertenze. 137-149. In: Klenner P (Eds).Vnitřní lékařství.Praha; Galén, 1998.
4. Landray MJ, Edmunds E, Lisaw-Hee FL, Hughes BA, Beewers DG, Lip GY. Abnormal low density lipoprotein subfraction profile in patients with untreated hypertension. QJM 2002; 95 (3): 165-171.
5. Zhao CX, Cui YH, Fan Q, et al. Small Dense Low-Density Lipoproteins and Associated Risk Factors in Patients with Stroke. Cerebrovasc Dis 2009; 27 (1): 99-104.
6. Rizzo M, Berneis K. Low density lipoprotein size and cardiovascular prevention. Eur J Int Med 2006; 17 (2): 77-80.
7. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipodol 1994; 5 (6): 394-403.
8. Shoji T, Hatsuda S, Tsuchikura S, et al. Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis. Atherosclerosis 2009; 202: 582-588.
9. Hoefner DM, Hodel SD, O'Brien JF, et al. Development of a rapid quantitative method for LDL subfraction with use of the Quantimetrix Lipoprint LDL system. Clin Chem 2001; 47 (2): 266-274.
10. Oravec S. Nová laboratórno-medicínska pomoc v diagnostike dyslipoproteinemii a kardiovaskularnych ochoreni: Identifikacia LDL podskupin. Med Milit Slov 2006; 8 (1): 28-32.
11. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82 (2): 495-506.
12. Van J, Pan J, Charles MA, Krauss R, Wong N, Wu X. Atherogenic lipid phenotype in a general group of subjects. Arch Pathol Lab Med 2007; 131(11): 1679-1685.
13. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002; 43 (9): 1363-1379.
14. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small dense low-density lipoprotein. Biochem Soc Trans 2003; 31 (Pt 5): 1066-1069.
15. Chait A, Brazq RL, Tribble DL, Krauss RM. Susceptibility of small, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94 (4): 350-356
16. Landry MJ, Sagar G, Muskin J, Murray S, Holder RL, Lip GY. Association of atherogenic low-density lipoprotein subfractions with carotid atheroscerosis. QJM 1998; 91 (5): 345-351.
17. Galeano NF, Al-Haideri M, Keysermann F, Rumsey SC, Deckelbaum RJ. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 1998; 39 (6), 1263-1273.
18. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81 (4A): 7B-12B.
19. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000; 86 (9): 943-949.
20. Taskinen MR. Diabetic dyslipidemia: from basic research to clinical practice. Diabetologia 2003; 46 (6): 733-749.
21. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus and cardiovascular disease. Am J Cardiol 2006; 97 (2A): 3A-11A.
22. Oravec S. Identifikácia subpopulácií LDL triedy - Aktuálny prínos v diagnostike porúch metabolizmu lipoproteínov a ochorení kardiovaskulárneho systému. Med Milit Slov 2006; 8 (1): 32-34.
23. Oravec S. Nové perspektívy v diagnostike porúch metabolizmu lipoproteínov - prínos v interpretácii výsledkov. Med Milit Slov 2007; 9 (1): 42-45.
24. Champan MJ, Chancharme L, Therondt P, Niqon F, Lepaqe S, Couturier M. Molecular mechanism of oxidation in small, dense LDL. Atherosclerosis 1999; 144 (Suppl 1): 7.